Search Result

Results for "

DA releasers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (1) Apoptosis (20) Bombesin Receptor (1) Dopamine Receptor (5) Dopamine Transporter (5) Endogenous Metabolite (18) Environmental Pollutants (2) Ferroptosis (19) GnRH Receptor (1) iGluR (19) Isotope-Labeled Compounds (5) mGluR (1) nAChR (8) NO Synthase (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Serotonin Transporter (1) Sodium Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (35)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (1)

Apoptosis (20)

Bombesin Receptor (1)

Dopamine Receptor (5)

Dopamine Transporter (5)

Endogenous Metabolite (18)

Environmental Pollutants (2)

Ferroptosis (19)

GnRH Receptor (1)

iGluR (19)

Isotope-Labeled Compounds (5)

mGluR (1)

nAChR (8)

NO Synthase (1)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

Serotonin Transporter (1)

Sodium Channel (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (3)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (35)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: RPE65

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14608

L-Glutamic acid Maximum Cited Publications 15 Publications Verification	Environmental Pollutants Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-14608A

L-Glutamic acid monosodium salt 10+ Cited Publications	Environmental Pollutants iGluR Apoptosis Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-14608S5

L-Glutamic acid-13C5 1 Publications Verification	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-B0979

Lobeline hydrochloride 1 Publications Verification α-Lobeline hydrochloride; L-Lobeline hydrochloride	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-14608S7

L-Glutamic acid-d5	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608R

L-Glutamic acid (Standard)	Reference Standards Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

HY-W419700

L-Glutamic acid ammonium 10+ Cited Publications	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid ammonium is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid ammonium has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid ammonium acts at ionotropic and?metabotropic glutamate receptors .

HY-14608S

L-Glutamic acid-13C	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W016145

L-Glutamic acid monosodium hydrate	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors .

HY-14608S2

L-Glutamic acid-15N	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S1

L-Glutamic acid-1-13C	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-P0048

(Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH 1 Publications Verification Surfagon	GnRH Receptor	Others
(Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH (Surfagon, Mwt 1167.34 Da) is an agonist of *gonadotropin-releasing* hormone (GnRH**). (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH can be used as an internal standard for the LC-MS analysis of leuprorelide acetate. (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH has potential applications in biochemical analysis and fertility .

HY-106865

Mivazerol	Dopamine Receptor Adrenergic Receptor	Cardiovascular Disease
Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research _.

HY-14608S6

L-Glutamic acid-5-13C	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-156331

VU6004909	mGluR	Neurological Disease
VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC₅₀s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy .

HY-B1423

Lobeline α-Lobeline; L-Lobeline	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) is a brain-penetrant nicotinic receptor agonist. Lobeline increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline is effective in smoking cessation .

HY-152170

bPiDI 1 Publications Verification	nAChR	Neurological Disease
bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-14608S4

L-Glutamic acid-13C5,15N,d5	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2	Apoptosis iGluR Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-101377A

R(+)-8-OH-DPAT hydrobromide (R)-8-Hydroxy-2-dipropylaminotetralin hydrobromide	5-HT Receptor	Neurological Disease
R(+)-8-OH-DPAT ((R)-8-Hydroxy-2-dipropylaminotetralin) hydrobromide is a potent 5-HT_1A agonist. R(+)-8-OH-DPAT potentiates SUL (HY-B1059)-induced dopamine (DA) release in the medial prefrontal cortex (mPFC) .

HY-176150

AMTG-DA1	Bombesin Receptor	Cancer
AMTG-DA1 is a *Gastrin-releasing* peptide receptor (GRPR)** ligand. AMTG-DA1 can be used in the study of cancer .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-B0979R

Lobeline hydrochloride (Standard) α-Lobeline hydrochloride (StanDArd); L-Lobeline hydrochloride (StanDArd)	Reference Standards nAChR Dopamine Transporter	Neurological Disease
Lobeline (hydrochloride) (Standard) is the analytical standard of Lobeline (hydrochloride). This product is intended for research and analytical applications. Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-107674

bPiDDB	nAChR	Neurological Disease
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-14608AR

L-Glutamic acid monosodium salt (Standard)	Reference Standards iGluR Apoptosis Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

HY-W681014

5-Fluoro-α-methyltryptamine hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
5-Fluoro-α-methyltryptamine hydrochloride may cause an increase in intracellular levels of 5-HT followed by an increase in 5-HT release. 5-Fluoro-α-methyltryptamine hydrochloride exhibits EC₅₀ values of 37 nM, 14 nM, 78 nM and 8.47 nM for DA, 5HT, NE and 5-HT2A, respectively .

HY-169467

5-Chloro-α-methyltryptamine	5-HT Receptor Dopamine Receptor	Neurological Disease
5-Chloro-α-methyltryptamine (Compound 7b) is a potent and selective dual *DA/5-HT* releaser and 5-HT_2a agonist. 5-Chloro-α-methyltryptamine releases DA and 5-HT with the EC₅₀ values of 54.3 nM and 16.2 nM, respectively. 5-Chloro-α-methyltryptamine can be used in the study of neurotransmitter .

HY-167636

7-Hydroxy ropinirole bromide SK&F 89124 bromide	Dopamine Receptor	Cardiovascular Disease Neurological Disease
7-Hydroxy ropinirole (SK&F 89124) bromide is a potent and highly selective DA₂ receptor agonist, and a derivative of N,N-di-n-propyldopamine (DPDA). In isolated perfused rabbit ear artery models, 7-Hydroxy ropinirole (bromide) exerts its DA₂ agonist effects by inhibiting neurotransmitter release or sympathetic nerve-induced responses. It shows potential for research in the fields of cardiovascular and neurological diseases .

HY-19186

PD-143188 CI 1007	Dopamine Receptor	Neurological Disease
PD-143188 (CI 1007) is a selective agonist targeting dopamine (DA) receptors, with K_i values of 25.5 nM and 16.6 nM for human D2 and D3 receptors, respectively and lower affinity for D4.2 receptors (K_i=90.9 nM). PD-143188 inhibits DA release, synthesis and metabolism, while reducing cellular cyclic AMP levels, exerting antipsychotic activity. PD-143188 is promising for research of psychopharmacology .

HY-P3168

Martentoxin	Potassium Channel NO Synthase	Cardiovascular Disease Inflammation/Immunology
Martentoxin, a 4,046 Da polypeptide toxin, is a large-conductance Ca ²⁺-activated K ⁺ (BK_Ca) channel inhibitor. Martentoxin attenuates NO release, inhibits iNOS activation and upregulates eNOS mRNA expression in HUVECs induced by TNF-α. Martentoxin can be used for vascular diseases research .

HY-105330

SIB 1663	nAChR	Neurological Disease
SIB 1663 is a conformationally restricted analog of nicotine. SIB-1663 selectively activatedα2β4 and α4β4 human recombinant neuronal nAChRs. SIB 1663 can increase DA and NE release. SIB 1663 can be used for the research of neurological disease .

HY-14608S9

L-Glutamic acid-15N,d5	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W061043

DOV-216,303	Serotonin Transporter Dopamine Transporter	Neurological Disease
DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC₅₀ values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .

HY-114659

AM-36	Sodium Channel Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
AM-36 is a neuroprotective agent with combined antioxidant and sodium channel blocking actions. AM-36 can inhibit cell apoptosis and ROS prodiction. AM-36 can reduce neuronal damage and DA release after middle cerebral artery occlusion in rats. AM-36 can be used for the researches of inflammation and neurological disease, such as stroke .

HY-14608S12

L-Glutamic acid-14C L-Glutamic acid-¹⁴C	iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-14C is L-Glutamic acid (HY-14608) labeled with the radioactive isotope carbon-14. L-Glutamic acid is an excitatory amino acid neurotransmitter and an agonist for all subtypes of glutamate receptors (metabotropic, NMDA, and AMPA). L-Glutamic acid acts as an agonist in the release of DA from dopaminergic nerve terminals and can be used in the study of neurological diseases .

HY-W016145S

L-Glutamic acid-13C5 hydrate salt	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
L-Glutamic acid- ¹³C₅ hydrate salt is the ¹³C labeled L-Glutamic acid hydrate salt. L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors.

HY-107674R

bPiDDB (Standard)	Reference Standards nAChR	Neurological Disease
bPiDDB (Standard) is the analytical standard of bPiDDB (HY-107674). This product is intended for research and analytical applications. bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

Cat. No.	Product Name	Target	Research Area

HY-P0048

(Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH 1 Publications Verification Surfagon	GnRH Receptor	Others
(Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH (Surfagon, Mwt 1167.34 Da) is an agonist of *gonadotropin-releasing* hormone (GnRH**). (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH can be used as an internal standard for the LC-MS analysis of leuprorelide acetate. (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH has potential applications in biochemical analysis and fertility .

HY-P3168

Martentoxin	Potassium Channel NO Synthase	Cardiovascular Disease Inflammation/Immunology
Martentoxin, a 4,046 Da polypeptide toxin, is a large-conductance Ca ²⁺-activated K ⁺ (BK_Ca) channel inhibitor. Martentoxin attenuates NO release, inhibits iNOS activation and upregulates eNOS mRNA expression in HUVECs induced by TNF-α. Martentoxin can be used for vascular diseases research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14608

L-Glutamic acid Maximum Cited Publications 15 Publications Verification	Structural Classification Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Environmental Pollutants Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-14608A

L-Glutamic acid monosodium salt 10+ Cited Publications	Structural Classification Microorganisms other families Animals Amino acids Plants Source Classification	Environmental Pollutants iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-B0979

Lobeline hydrochloride 1 Publications Verification α-Lobeline hydrochloride; L-Lobeline hydrochloride	Alkaloids Campanulaceae Pyridine Alkaloids Plants Lobelia chinensis Lour. Source Classification	nAChR Dopamine Transporter
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-14608R

L-Glutamic acid (Standard)	Structural Classification Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Reference Standards Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

HY-B1423

Lobeline α-Lobeline; L-Lobeline	Alkaloids Other Alkaloids Campanulaceae Plants Lobelia chinensis Lour. Source Classification	nAChR Dopamine Transporter
Lobeline (α-Lobeline) is a brain-penetrant nicotinic receptor agonist. Lobeline increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline is effective in smoking cessation .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	Alkaloids other families Pyridine Alkaloids Plants Endogenous metabolite Source Classification	nAChR Dopamine Transporter
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-B0979R

Lobeline hydrochloride (Standard) α-Lobeline hydrochloride (StanDArd); L-Lobeline hydrochloride (StanDArd)	Alkaloids Structural Classification Campanulaceae Pyridine Alkaloids Plants Lobelia chinensis Lour. Source Classification	Reference Standards nAChR Dopamine Transporter
Lobeline (hydrochloride) (Standard) is the analytical standard of Lobeline (hydrochloride). This product is intended for research and analytical applications. Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .

HY-14608AR

L-Glutamic acid monosodium salt (Standard)	Structural Classification Microorganisms other families Animals Amino acids Plants Source Classification	Reference Standards iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

Cat. No.	Product Name	Chemical Structure

HY-14608S5

L-Glutamic acid-13C5 1 Publications Verification
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W016145S

L-Glutamic acid-13C5 hydrate salt

L-Glutamic acid- ¹³C₅ hydrate salt is the ¹³C labeled L-Glutamic acid hydrate salt. L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

DA releasers

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products